Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Sarah Rouse x
  • Refine by access: Open Access content only x
Clear All Modify Search
Affiong Ika Oqua Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK

Search for other papers by Affiong Ika Oqua in
Google Scholar
PubMed
Close
,
Yusman Manchanda Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK

Search for other papers by Yusman Manchanda in
Google Scholar
PubMed
Close
,
Emma Rose McGlone Department of Surgery and Cancer, Imperial College London, London, UK

Search for other papers by Emma Rose McGlone in
Google Scholar
PubMed
Close
,
Ben Jones Section of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK

Search for other papers by Ben Jones in
Google Scholar
PubMed
Close
,
Sarah Rouse Department of Life Sciences, Imperial College, London, UK

Search for other papers by Sarah Rouse in
Google Scholar
PubMed
Close
, and
Alejandra Tomas Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK

Search for other papers by Alejandra Tomas in
Google Scholar
PubMed
Close

The glucagon receptor family are typical class B1 G protein-coupled receptors (GPCRs) with important roles in metabolism, including the control of pancreas, brain, and liver function. As proteins with seven transmembrane domains, GPCRs are intimately in contact with lipid bilayers and therefore can be putatively regulated by interactions with their lipidic components, including cholesterol, sphingolipids, and other lipid species. Additionally, these receptors, as well as the agonists they bind to, can undergo lipid modifications, which can influence their binding capacity and/or elicit modified or biased signalling profiles. While the effect of lipids, and in particular cholesterol, has been widely studied for other GPCR classes, information about their role in regulating the glucagon receptor family is only beginning to emerge. Here we summarise our current knowledge on the effects of cholesterol modulation of glucagon receptor family signalling and trafficking profiles, as well as existing evidence for specific lipid–receptor binding and indirect effects of lipids via lipid modification of cognate agonists. Finally, we discuss the different methodologies that can be employed to study lipid–receptor interactions and summarise the importance of this area of investigation to increase our understanding of the biology of this family of metabolically relevant receptors.

Open access